Tolerance Induction to Factor VIII by Transient Co-administration with Rapamycin

Background Formation of inhibitory antibodies is a frequent and serious complication of factor VIII (F.VIII) replacement therapy for the X-linked bleeding disorder hemophilia A. Similarly, hemophilia A mice develop high-titer inhibitors to recombinant human F.VIII after a few intravenous injections.